Egg allergy trials halted by Aimmune; Atlas closes its 13th fund for $450M
A Phase II trial for Aimmune’s drug to treat children and young adults with egg allergies has been terminated.
The trial was terminated on Feb. 28, according to its clinicaltrials.gov site. In an emailed statement to Endpoints News, a company spokesperson said:
“Aimmune made the decision to terminate the study of AR201 in a characterized oral desensitization immunotherapy (CODIT™) regimen in hen egg-allergic subjects aged 4 to 26 years, inclusive, based on difficulties in meeting enrollment goals, especially during the COVID-19 pandemic, and not for reasons relating to any concerns regarding quality, safety, or efficacy.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.